Cefovecin

	WikiDoc Resources for Cefovecin
Articles
Most recent articles on Cefovecin Most cited articles on Cefovecin Review articles on Cefovecin Articles on Cefovecin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cefovecin Images of Cefovecin Photos of Cefovecin Podcasts & MP3s on Cefovecin Videos on Cefovecin
Evidence Based Medicine
Cochrane Collaboration on Cefovecin Bandolier on Cefovecin TRIP on Cefovecin
Clinical Trials
Ongoing Trials on Cefovecin at Clinical Trials.gov Trial results on Cefovecin Clinical Trials on Cefovecin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cefovecin NICE Guidance on Cefovecin NHS PRODIGY Guidance FDA on Cefovecin CDC on Cefovecin
Books
Books on Cefovecin
News
Cefovecin in the news Be alerted to news on Cefovecin News trends on Cefovecin
Commentary
Blogs on Cefovecin
Definitions
Definitions of Cefovecin
Patient Resources / Community
Patient resources on Cefovecin Discussion groups on Cefovecin Patient Handouts on Cefovecin Directions to Hospitals Treating Cefovecin Risk calculators and risk factors for Cefovecin
Healthcare Provider Resources
Symptoms of Cefovecin Causes & Risk Factors for Cefovecin Diagnostic studies for Cefovecin Treatment of Cefovecin
Continuing Medical Education (CME)
CME Programs on Cefovecin
International
Cefovecin en Espanol Cefovecin en Francais
Business
Cefovecin in the Marketplace Patents on Cefovecin
Experimental / Informatics
List of terms related to Cefovecin

Cefovecin
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy; category	do not administer to pregnant cat or during breeding or lactation period.;
Routes of; administration	dorsoscapular subcutaneous injection
ATCvet code	Template:Infobox drug/formatATCvet; Template:Infobox drug/formatATCvet;
Legal status
Legal status	Veterinary use only;
Pharmacokinetic data
Protein binding	Dogs: 98.5%, Cats: 99.8%
Metabolism	none
Elimination half-life	Dogs: 133 hours, Cats: 166 hours
Excretion	unchanged in urine/bile
Identifiers
	IUPAC name (7R)-7-([(2Z)- 2-(2-amino- 1,3-thiazol- 4-yl)- 2-methoxyiminoacetyl]amino)- 8-oxo- 3-[(2S)-oxolan- 2-yl]- 5-thia- 1-azabicyclo[4.2.0]oct- 2-ene- 2-carboxylic acid;
CAS Number	234096-34-5 ;
PubChem CID	9578573;
ChemSpider	7851662 ;
UNII	0D1OL46ZIE;
ChEMBL	ChEMBL2104475 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C17H19N5O6S2
Molar mass	453.49 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=N\OC)\c3nc(sc3)N)[C@H]4OCCC4)C(=O)O;
	InChI InChI=1S/C17H19N5O6S2/c1-27-21-10(8-6-30-17(18)19-8)13(23)20-11-14(24)22-12(16(25)26)7(5-29-15(11)22)9-3-2-4-28-9/h6,9,11,15H,2-5H2,1H3,(H2,18,19)(H,20,23)(H,25,26)/b21-10+/t9-,11+,15+/m0/s1 ; Key:ZJGQFXVQDVCVOK-MSUXKOGISA-N ;
(what is this?) (verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Cefovecin (INN) is an antibiotic of the cephalosporin class, licensed for the treatment of skin infections in cats and dogs. It is marketed by Zoetis under the trade name Convenia. It is the first single-dose injectable antibiotic for dogs and cats that assures owner compliance with dosing for the animal. It is used for the treatment of skin infections caused by Pasturella multocida in cats, and Streptococcus intermedius/S. canis in dogs. The advantage of using injectable antibiotics is not missing a dose that can allow partially resistant microbes to recover during missed doses. It is highly effective, but should not be used in pregnant or lactating animals or in animals with a history of allergies to penicillin or cephalosporin drugs.^[1]

Approval and usage

Cefovecin was first authorized for use in the European Union in June 2006,^[2] and was approved for use in the United States in June 2008.^[3]

It is approved as a broad-spectrum, fourth-generation cephalosporin for subcutaneous injection lasting 14 days for treating skin and soft tissue infections.^[4]

Precautions

Contraindications include known allergies to cefovecin or antibiotics containing β-lactam rings such as penicillin or cephalosporins. Adverse reactions can include anaphylaxis. It is not for use in humans and should be kept out of reach of children. Individuals with similar known allergies should avoid dermal contact when handling the drugs.

Adverse reactions in dogs can include lethargy, decreased appetite, vomiting, diarrhea, blood in feces, and flatulence. Adverse reactions in cats can include vomiting, diarrhea, decreased appetite, lethargy, odd hyperactive behavior, and inappropriate urination. Mildly increased serum ALT and gamma glutamyl transferase have been noted.^[5]

Effectiveness

Cefovecin functions by interfering with cell wall synthesis. The chemical covalently binds to the so-called penicillin-binding proteins. Due to the high protein-binding of the chemical, it is not effective against Pseudomonas spp., or enterococci.

In drug studies, cefovecin administered to dogs was 92.4% effective against skin infections (secondary superficial pyoderma, abscesses, and infected wounds). In cats, it was 96.8% effective against skin infections.^[6]

References

↑ Pfizer Animal Health. "Pfizer Convenia" (PDF). Pfizer. Retrieved 29 January 2013.
↑ "European Public Assessment Report for Convenia (from the EMEA website)". Retrieved 2008-07-11.
↑ "FDA Approves First and Only Single-dose Antibiotic for Dogs and Cats" (Press release). Pfizer Inc. 2008-06-30. Retrieved 2008-07-11.
↑ Pfizer Animal Health. "Convenia". Pfizer. Retrieved 29 January 2013.
↑ Pfizer Animal Health. "Pfizer Convenia" (PDF). Pfizer. Retrieved 29 January 2013.
↑ Pfizer Animal Health. "Pfizer Convenia" (PDF). Pfizer. Retrieved 29 January 2013.

External links

Template:PubChem - Cefovecin sodium
Official website by Pfizer

[1] Pfizer Animal Health. "Pfizer Convenia" (PDF). Pfizer. Retrieved 29 January 2013.

[2] "European Public Assessment Report for Convenia (from the EMEA website)". Retrieved 2008-07-11.

[3] "FDA Approves First and Only Single-dose Antibiotic for Dogs and Cats" (Press release). Pfizer Inc. 2008-06-30. Retrieved 2008-07-11.

[4] Pfizer Animal Health. "Convenia". Pfizer. Retrieved 29 January 2013.

[5] Pfizer Animal Health. "Pfizer Convenia" (PDF). Pfizer. Retrieved 29 January 2013.

[6] Pfizer Animal Health. "Pfizer Convenia" (PDF). Pfizer. Retrieved 29 January 2013.

[1]

[2]

[3]

[4]

[5]

[6]

Clinical data

AHFS/Drugs.com	International Drug Names
Pregnancy category	do not administer to pregnant cat or during breeding or lactation period.
Routes of administration	dorsoscapular subcutaneous injection
ATCvet code	Template:Infobox drug/formatATCvet Template:Infobox drug/formatATCvet
Legal status
Legal status	Veterinary use only
Pharmacokinetic data
Protein binding	Dogs: 98.5%, Cats: 99.8%
Metabolism	none
Elimination half-life	Dogs: 133 hours, Cats: 166 hours
Excretion	unchanged in urine/bile
Identifiers
IUPAC name (7R)-7-([(2Z)- 2-(2-amino- 1,3-thiazol- 4-yl)- 2-methoxyiminoacetyl]amino)- 8-oxo- 3-[(2S)-oxolan- 2-yl]- 5-thia- 1-azabicyclo[4.2.0]oct- 2-ene- 2-carboxylic acid
CAS Number	234096-34-5^Y
PubChem CID	9578573
ChemSpider	7851662^N
UNII	0D1OL46ZIE
ChEMBL	ChEMBL2104475^N
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₇H₁₉N₅O₆S₂
Molar mass	453.49 g/mol
3D model (JSmol)	Interactive image
SMILES O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=N\OC)\c3nc(sc3)N)[C@H]4OCCC4)C(=O)O
InChI InChI=1S/C17H19N5O6S2/c1-27-21-10(8-6-30-17(18)19-8)13(23)20-11-14(24)22-12(16(25)26)7(5-29-15(11)22)9-3-2-4-28-9/h6,9,11,15H,2-5H2,1H3,(H2,18,19)(H,20,23)(H,25,26)/b21-10+/t9-,11+,15+/m0/s1^N Key:ZJGQFXVQDVCVOK-MSUXKOGISA-N^N
^NY (what is this?) (verify)